Major Companies in China Omeprazole Market | Insights & Market Overview 2026

China Omeprazole Market Overview

According to 6Wresearch, the China omeprazole market is projected for steady expansion, fueled by the high prevalence of gastric ulcers and GERD among the aging population. As a core member of the Proton Pump Inhibitor (PPI) class, omeprazole is used as a primary treatment for acid-related diseases in China. The market is further boosted by China's "Healthy China 2030" initiative and the implementation of Volume-Based Procurement (VBP) policies that standardize pricing and promote accessibility.

Competitive Landscape

The competitive landscape of the China omeprazole market is characterized by the coexistence of established multinational corporations and a consolidating domestic manufacturing sector. To meet the growing demand for accuracy and safety, these companies are investing heavily in "Quality by Design" (QbD) production and automated bioequivalence testing.

Below is a list of leading players operating in the China Omeprazole Market:

1. AstraZeneca PLC

The original developer of omeprazole (Losec), AstraZeneca maintains a massive footprint in China, focusing on high-end clinical applications and educational outreach for gastric health.

2. Yangtze River Pharmaceutical Group (YRPG)

A dominant domestic leader, YRPG is a primary supplier of both oral and injectable omeprazole, leveraging its extensive hospital distribution network to maintain a top market position.

3. CSPC Pharmaceutical Group Limited

Operating through major subsidiaries like CSPC Ouyi, the group produces high-quality omeprazole sodium for injection, catering to the acute care segment in China's public health system.

4. Jiangsu Hengrui Pharmaceuticals Co., Ltd.

As one of China's most innovative pharmaceutical firms, Hengrui invests heavily in R&D to enhance the stability and delivery of its gastrointestinal product portfolio.

5. Sino Biopharmaceutical Limited

A major conglomerate in the anti-ulcer space, this group specializes in high-barrier generic formulations that meet international quality standards for clinical efficacy.

6. Bayer AG

Bayer maintains a strong retail presence in China, providing over-the-counter (OTC) digestive health solutions alongside its specialized prescription pharmaceutical lineup.

7. Shandong Xinhua Pharmaceutical Co., Ltd.

A critical manufacturer of Active Pharmaceutical Ingredients (APIs), Xinhua provides the foundational omeprazole powder used by numerous domestic and global formulators.

8. Zhejiang Huahai Pharmaceutical Co., Ltd.

Known for its international regulatory expertise, Huahai produces omeprazole capsules that are widely used in domestic hospitals following major procurement wins.

9. North China Pharmaceutical Group (NCPC)

A legacy state-owned enterprise, NCPC provides stable, high-volume production of essential medications, including affordable omeprazole variants for the mass market.

10. Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Specializes in the manufacture of high-stability oral solids, focusing on the southern China regional market and various retail pharmacy chains.

11. Livzon Pharmaceutical Group Inc.

A comprehensive group that integrates R&D, production, and sales. Livzon is a dominant force in the digestive health field, offering both enteric-coated tablets and high-stability injectable formulations.

12. Sichuan Kelun Pharmaceutical Co., Ltd.

Known for its massive scale in intravenous (IV) solutions, Kelun is a primary supplier of large-volume parenteral omeprazole sodium, utilized heavily in clinical inpatient settings across China.

13. Hainan Haiyao Co., Ltd.

A legacy manufacturer in the Chinese pharmaceutical landscape, Hainan Haiyao produces a wide range of gastrointestinal medicines and has expanded its omeprazole production to meet regional hospital demand.

14. Luye Pharma Group

Luye focuses on innovative drug delivery systems. The company specializes in high-quality generic omeprazole that utilizes advanced coating technology to ensure consistent therapeutic release.